6 search results for: bethany-christmann

On June 25th, the FDA approved GW Pharmaceuticals’ Epidiolex (cannabidiol, or CBD) for the treatment of Lennox-Gastaut syndrome (LGS) and Dravet...

“Is the benefit-risk profile of cannabidiol favorable for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome...

On February 6th, Zogenix announced that the FDA had granted “breakthrough therapy” designation to ZX-008 (low-dose fenfluramine), its Phase III...

A core unmet need in Parkinson’s disease (PD) is a new way to address “off” time, a term that refers to the return of motor symptoms when a...

The late-phase Parkinson’s disease (PD) pipeline has swelled, but new drugs face a challenging U.S. access and reimbursement environment. While...

On April 29th, the FDA approved Acadia Pharmaceuticals’ Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with...